ArticleThe Journal of clinical and aesthetic dermatology2022
Androgenetic Alopecia and Metabolic Syndrome: Is Alarin a Missing Link?
Article in The Journal of clinical and aesthetic dermatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.
- Prevalence of the metabolic syndrome in African populations: A systematic review and meta-analysis.PloS one · 2023Pooled it
- Association of Hypertension and Serum Aldosterone Levels in Male Patients with Androgenetic Alopecia: A Case-Control Study.Journal of multidisciplinary healthcare · 2026Article
- Consensus Recommendations for the Management of Androgenetic Alopecia in Egypt: A Modified Delphi Study.Clinical, cosmetic and investigational dermatology · 2025Article
- Article
- Male-pattern hair loss: Comprehensive identification of the associated genes as a basis for understanding pathophysiology.Medizinische Genetik : Mitteilungsblatt des Berufsverbandes Medizinische Genetik e.V · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The field of research into the probable link between androgenetic alopecia (AGA) and metabolic syndrome (MetS) is rapidly expanding. The exact underlying pathogenesis yet to be identified. Alarin, a galanin neuropeptide, found to be elevated in patients with metabolic syndrome and may represent a potential link between AGA and MetS. Objective: The aim of this study was to assess serum levels of alarin in patients with AGA and investigate its possible correlation, if any, with criteria of MetS in those patients. Methods: The study included 50 male patients with AGA and 30 healthy controls. Weight, height, waist circumference, and body mass index (BMI) were all measured. Systolic and diastolic blood pressure readings were recorded. Serum level of lipids, fasting blood glucose (FBG) and alarin were also assessed. Results: Anthropometric measures, serum lipids, FBG, and serum alarin were much higher in patients with AGA compared to controls ( Conclusion: Serum level of alarin might represent a potential link between AGA and MetS, opening the door for better understanding of the pathogenesis of both conditions and the possible association between them.
Indexed as
Identifiers
35942015PMC9345189W4298045410What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.